At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GLUE Monte Rosa Therapeutics
Market Closed 07-05 16:00:00 EDT
3.64
-0.25
-6.43%
盘后3.95
+0.31+8.52%
19:24 EDT
High3.90
Low3.61
Vol335.14K
Open3.83
D1 Closing3.89
Amplitude7.46%
Mkt Cap222.55M
Tradable Cap126.15M
Total Shares61.14M
T/O1.25M
T/O Rate0.97%
Tradable Shares34.66M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Neumora Therapeutics, Inc. (NMRA) and Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.